JP7295799B2 - 抗原特異的抗体を選択的に枯渇させるための融合タンパク質 - Google Patents

抗原特異的抗体を選択的に枯渇させるための融合タンパク質 Download PDF

Info

Publication number
JP7295799B2
JP7295799B2 JP2019529975A JP2019529975A JP7295799B2 JP 7295799 B2 JP7295799 B2 JP 7295799B2 JP 2019529975 A JP2019529975 A JP 2019529975A JP 2019529975 A JP2019529975 A JP 2019529975A JP 7295799 B2 JP7295799 B2 JP 7295799B2
Authority
JP
Japan
Prior art keywords
seq
seldeg
antigen
fragment
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019529975A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020500885A (ja
JP2020500885A5 (OSRAM
Inventor
オーバー，エリザベス・サリー・ウォード
デバナボイナ，ベンカタ・シバ・チャラン
オーバー，ライムンド・ヨハネス
Original Assignee
ザ テキサス エー アンド エム ユニバーシティー システム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ テキサス エー アンド エム ユニバーシティー システム filed Critical ザ テキサス エー アンド エム ユニバーシティー システム
Publication of JP2020500885A publication Critical patent/JP2020500885A/ja
Publication of JP2020500885A5 publication Critical patent/JP2020500885A5/ja
Priority to JP2023095266A priority Critical patent/JP2023113894A/ja
Application granted granted Critical
Publication of JP7295799B2 publication Critical patent/JP7295799B2/ja
Priority to JP2025094049A priority patent/JP2025131743A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
JP2019529975A 2016-12-02 2017-12-01 抗原特異的抗体を選択的に枯渇させるための融合タンパク質 Active JP7295799B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023095266A JP2023113894A (ja) 2016-12-02 2023-06-09 抗原特異的抗体を選択的に枯渇させるための融合タンパク質
JP2025094049A JP2025131743A (ja) 2016-12-02 2025-06-05 抗原特異的抗体を選択的に枯渇させるための融合タンパク質

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662429367P 2016-12-02 2016-12-02
US62/429,367 2016-12-02
PCT/US2017/064186 WO2018102668A1 (en) 2016-12-02 2017-12-01 Fusion proteins for selectively depleting antigen-specific antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023095266A Division JP2023113894A (ja) 2016-12-02 2023-06-09 抗原特異的抗体を選択的に枯渇させるための融合タンパク質

Publications (3)

Publication Number Publication Date
JP2020500885A JP2020500885A (ja) 2020-01-16
JP2020500885A5 JP2020500885A5 (OSRAM) 2021-01-21
JP7295799B2 true JP7295799B2 (ja) 2023-06-21

Family

ID=62242041

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019529975A Active JP7295799B2 (ja) 2016-12-02 2017-12-01 抗原特異的抗体を選択的に枯渇させるための融合タンパク質
JP2023095266A Pending JP2023113894A (ja) 2016-12-02 2023-06-09 抗原特異的抗体を選択的に枯渇させるための融合タンパク質
JP2025094049A Pending JP2025131743A (ja) 2016-12-02 2025-06-05 抗原特異的抗体を選択的に枯渇させるための融合タンパク質

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023095266A Pending JP2023113894A (ja) 2016-12-02 2023-06-09 抗原特異的抗体を選択的に枯渇させるための融合タンパク質
JP2025094049A Pending JP2025131743A (ja) 2016-12-02 2025-06-05 抗原特異的抗体を選択的に枯渇させるための融合タンパク質

Country Status (7)

Country Link
US (2) US11459396B2 (OSRAM)
EP (1) EP3548073A4 (OSRAM)
JP (3) JP7295799B2 (OSRAM)
CN (1) CN110799210A (OSRAM)
AU (2) AU2017366674B2 (OSRAM)
CA (1) CA3045797A1 (OSRAM)
WO (1) WO2018102668A1 (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020518240A (ja) * 2017-01-17 2020-06-25 ザ テキサス エー アンド エム ユニバーシティー システム 標的細胞のエンドリソソーム区画へのカーゴ分子の送達の向上のためのエンドリソソーム標的化コンジュゲート
CN111182915A (zh) 2017-08-15 2020-05-19 金德雷德生物科学股份有限公司 兽药用IgG Fc变体
EP3715375A1 (en) 2019-03-23 2020-09-30 Ablevia biotech GmbH Compound for the prevention or treatment of pre-eclampsia
EP3715376A1 (en) 2019-03-23 2020-09-30 Ablevia biotech GmbH Compound for the prevention or treatment of myasthenia gravis
EP3715374A1 (en) 2019-03-23 2020-09-30 Ablevia biotech GmbH Compound for the sequestration of undesirable antibodies in a patient
US11986536B2 (en) 2019-03-23 2024-05-21 Ablevia Biotech Gmbh Compound for the sequestration of undesirable antibodies in a patient
US20230381334A1 (en) 2020-09-23 2023-11-30 Ablevia Biotech Gmbh Compound for the sequestration of undesirable antibodies in a patient
AU2021347583A1 (en) 2020-09-23 2023-05-25 Ablevia Biotech Gmbh Compound for increasing efficacy of viral vectors
AU2021347581A1 (en) 2020-09-23 2023-05-18 Ablevia Biotech Gmbh Compound for the prevention or treatment of autoantibody-mediated conditions
TW202228784A (zh) 2020-09-23 2022-08-01 奧地利商艾柏力維亞生技有限公司 用以於一患者中螯合非預期的抗ｐｅｇ抗體的化合物
WO2022063887A1 (en) 2020-09-23 2022-03-31 Ablevia Biotech Gmbh Compound for increasing the efficacy of factor viii replacement therapy
JP2023543444A (ja) 2020-09-24 2023-10-16 アブレヴィア バイオテック ゲーエムベーハー 重症筋無力症の予防又は治療のための化合物
WO2023180502A1 (en) 2022-03-24 2023-09-28 Ablevia Biotech Gmbh Compound for increasing efficacy of oncolytic viruses
CN119013290A (zh) 2022-04-13 2024-11-22 Ose免疫疗法公司 用于选择性清除抗体的新型分子
WO2024092033A1 (en) * 2022-10-26 2024-05-02 Amgen Inc. Multispecific molecules for clearance of immunoglobulins in the treatment of autoantibody-induced diseases
CN120624489B (zh) * 2025-08-18 2025-12-02 天津医科大学总医院 一种嵌合aqp4抗体受体、caar-t细胞及应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012503007A (ja) 2008-09-17 2012-02-02 ゼンコア インコーポレイテッド ＩｇＥ媒介性疾患を治療するための新規組成物および方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1311549A2 (en) 2000-08-22 2003-05-21 Micromet AG Composition for the elimination of autoreactive b-cells
AU2002236499A1 (en) 2000-11-30 2002-06-11 Uab Research Foundation Receptor-mediated uptake of peptides that bind the human transferrin receptor
US20060235208A1 (en) * 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
EP1697520A2 (en) * 2003-12-22 2006-09-06 Xencor, Inc. Fc polypeptides with novel fc ligand binding sites
US8163881B2 (en) * 2005-05-31 2012-04-24 The Board Of Regents Of The University Of Texas System Immunoglobulin molecules with improved characteristics
SI2697257T1 (sl) * 2011-04-13 2017-02-28 Bristol-Myers Squibb Company FC fuzijski proteini, ki vsebujejo nove linkerje ali razmestitve
CN110272484A (zh) * 2011-05-05 2019-09-24 阿尔布梅迪克斯医疗有限公司 白蛋白变体
PL3087095T3 (pl) 2013-12-24 2020-03-31 Argenx Bvba Antagoniści fcrn i sposoby stosowania
US20160060358A1 (en) * 2014-08-28 2016-03-03 California Institute Of Technology Induction of antigen-specific tolerance
US20170334962A1 (en) 2016-05-19 2017-11-23 Texas A&M University System FcRn-TARGETED ANTIGEN FUSION PROTEINS

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012503007A (ja) 2008-09-17 2012-02-02 ゼンコア インコーポレイテッド ＩｇＥ媒介性疾患を治療するための新規組成物および方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
The International Journal of BiologicalMarkers, 2004, Vol.19, No.3, p.213-220

Also Published As

Publication number Publication date
WO2018102668A1 (en) 2018-06-07
JP2020500885A (ja) 2020-01-16
US20200031948A1 (en) 2020-01-30
US20230087965A1 (en) 2023-03-23
CA3045797A1 (en) 2018-06-07
AU2017366674B2 (en) 2025-01-02
US12404339B2 (en) 2025-09-02
EP3548073A4 (en) 2020-07-22
AU2025202131A1 (en) 2025-04-10
US11459396B2 (en) 2022-10-04
EP3548073A1 (en) 2019-10-09
JP2023113894A (ja) 2023-08-16
JP2025131743A (ja) 2025-09-09
CN110799210A (zh) 2020-02-14
AU2017366674A1 (en) 2019-06-20

Similar Documents

Publication Publication Date Title
JP7295799B2 (ja) 抗原特異的抗体を選択的に枯渇させるための融合タンパク質
CN109715663B (zh) 结合生长抑素受体2的异源二聚抗体
JP7065766B2 (ja) 改変ｊ鎖を有する結合分子
US20230390413A1 (en) Endolysosomal targeting conjugates for improved delivery of cargo molecules to the endolysosomal compartment of target cells
US20160009824A1 (en) Tetravalent bispecific antibodies
TW202400642A (zh) 抗ＣＤ２８ｘ抗ＰＳＭＡ抗體
KR20230141817A (ko) 이중특이 항체
JP2024538050A (ja) メソテリン結合タンパク質及びその使用
CN119698294A (zh) 结合γ-δT细胞受体的变体抗体
TW202525853A (zh) 抗ｃｄ２０ｘ抗ｃｄ２８組合療法
WO2023028715A1 (en) Fc variant with high thermal stability and attenuated effector function
US20250382348A1 (en) Approaches for the selective depletion of pla2r-specific antibodies
US20250109204A1 (en) Compositions comprising antibodies that bind gamma-delta t cell receptors
KR20240052030A (ko) 높은 열 안정성 및 감쇠된 효과기 기능을 갖는 fc 변이체
WO2025087436A1 (zh) 基于t细胞受体的多特异性多肽分子及其组合物和用途
JP2022525261A (ja) ビスタ結合抗体およびその使用
HK40007765A (en) Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201201

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210930

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211019

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220119

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220419

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220713

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221013

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230308

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230310

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230510

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230609

R150 Certificate of patent or registration of utility model

Ref document number: 7295799

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150